📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,098
All-time analysed
43,626
Positive
6,746
Negative
92,878
Neutral
8,780
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
848 announcements match the current filters (relevance ≥ 5).
Tasty Bite Shareholders Reject Material Related Party Transactions with Mars Food UK
Tasty Bite Eatables shareholders have rejected two critical resolutions regarding material related party transactions (RPT) with Mars Food UK and Preferred Brands International for FY 2025-26 and FY 2026-27. Over 98% of the voting public shareholders, including institutions, opposed these RPT resolutions, leading to their failure. While the RPTs were blocked, shareholders did approve revised remuneration packages for the Managing Director, Whole Time Director, and Chairman. This significant dissent on RPTs could pose operational challenges given the company's integrated business model with its global parent.
Key Highlights
Resolution 1 for RPTs in FY 2026-27 failed with 98.68% of polled votes cast against the proposal.
Resolution 5 for continuing transactions with Mars Food UK for FY 2025-26 failed with 98.71% votes against.
Public institutional investors voted overwhelmingly against RPTs, with 91,841 votes against versus only 1,291 in favor.
Remuneration revisions for MD Dilen Gandhi and WTD Shashank Shekhar passed with over 95% total favor votes.
The postal ballot saw participation from 19,682 shareholders as of the March 27, 2026 record date.
👀 What to Watch
Investors should exercise caution as the rejection of material related party transactions may disrupt the company's supply chain and sales to group entities. Monitor for management's response or revised proposals to address shareholder concerns regarding transaction terms.
SBI Shortlists 8 Candidates for Election of 4 Directors to Central Board
State Bank of India (SBI) has released the list of eight validly nominated candidates for the election of four Directors to its Central Board. The election is scheduled to take place during the General Meeting of Shareholders on May 15, 2026. The candidates possess diverse expertise in areas such as Chartered Accountancy, Actuarial science, IT strategy, and risk management. This process is being conducted under Section 19(c) of the State Bank of India Act, 1955, and complies with the latest RBI governance directions.
Key Highlights
Eight candidates nominated for the election of four Directors to the Central Board.
Election scheduled for May 15, 2026, at 03:00 PM via Video Conferencing.
Candidate pool includes 4 Chartered Accountants and experts with over 30-40 years of experience in banking and insurance.
Nominations are compliant with RBI (Commercial Banks - Governance) Directions, 2025.
Candidates include a mix of existing directors like Dharmendra Singh Shekhawat and new industry veterans.
👀 What to Watch
Shareholders should review the professional backgrounds of the eight candidates to participate effectively in the voting process on May 15. The selection of directors with strong compliance and digital transformation backgrounds is a positive sign for the bank's long-term governance.
Nath Bio-Genes FY26 Revenue Grows 19% to ₹4,316 Mn; Margins Contract to 12%
Nath Bio-Genes reported a strong 19% YoY revenue growth for FY26, reaching ₹4,316 million, driven by robust performance in Cotton (+28% value) and Maize (+78% value). However, profitability was under pressure as EBITDA remained flat at ₹525 million and Gross Margins compressed from 63% to 56%. A key highlight is the international expansion milestone, with Uzbekistan contributing ₹150 million to the top line for the first time. Despite the revenue jump, PAT (adjusted) declined by 8% YoY to ₹384 million.
Key Highlights
Revenue increased by 19% YoY to ₹4,316 Mn, while EBITDA remained stagnant at ₹525 Mn.
Cotton Bt volumes grew 22.35% with average realization rising to ₹293/kg.
Gross Margin saw a significant contraction to 56% in FY26 from 63% in the previous year.
International operations in Uzbekistan achieved a landmark ₹150 Mn revenue contribution.
Net Debt increased significantly to ₹510 Mn from ₹235 Mn in FY25.
👀 What to Watch
Investors should monitor the company's ability to recover margins and manage rising debt levels despite healthy top-line growth. The successful scale-up in Uzbekistan and growth in the Maize segment are positive long-term indicators to watch.
Nath Bio-Genes FY26 Revenue Up 19% to ₹431.6 Cr; Recommends ₹2 Dividend
Nath Bio-Genes (India) Limited reported a 19.1% growth in annual revenue for FY26, reaching ₹431.60 crore compared to ₹362.31 crore in FY25. Annual net profit saw a modest increase of 5.4% to ₹44.43 crore, despite a weaker fourth quarter where profit dipped to ₹3.79 crore. The Board has recommended a dividend of ₹2 per share (20% of face value). A significant management update includes the more than doubling of the Managing Director's remuneration to ₹1.44 crore per annum.
Key Highlights
Annual Revenue from operations grew 19.1% YoY to ₹431.60 crore from ₹362.31 crore.
Full-year Net Profit increased to ₹44.43 crore compared to ₹42.14 crore in the previous fiscal.
Recommended a final dividend of ₹2.00 per equity share (20%) for FY 2025-26.
Managing Director's annual remuneration increased by 118% from ₹66 lakhs to ₹1.44 crore.
Inventory levels rose significantly to ₹444.60 crore from ₹330.71 crore YoY, indicating aggressive positioning for the next season.
👀 What to Watch
Investors should view the steady annual top-line growth and dividend payout positively, though the sharp hike in executive pay and rising inventory levels warrant close monitoring. The stock remains a play on the Indian agricultural cycle and seed demand.
SBI Card Q4 FY26 PAT Rises 14% to ₹609 Cr; Asset Quality Improves as GNPA Drops to 2.41%
SBI Cards reported a steady Q4 FY26 with PAT growing 14% YoY to ₹609 crores, driven by a 31% surge in total spends reaching ₹1.15 trillion. Asset quality showed significant improvement as GNPA fell to 2.41% and credit costs moderated by 55 bps sequentially to 7.7%. Net Interest Margins (NIM) remained healthy at 11.1%, supported by a lower cost of funds at 6.4%. The company maintained its market position with an 18.6% share in cards-in-force and declared an interim dividend of ₹2.50 per share.
Key Highlights
Full-year FY26 PAT reached ₹2,167 crores, marking a 13% YoY growth with total revenue at ₹20,708 crores.
Asset quality improved significantly with GNPA reducing by 46 bps QoQ to 2.41% and Stage 2 assets falling to ₹2,090 crores.
Total spends for Q4 grew 31% YoY to ₹1.15 trillion, while retail spends for FY26 hit a record ₹3.54 trillion.
Net Interest Margin (NIM) for FY26 improved by 31 bps YoY to 11.2%, aided by a 71 bps reduction in the annual cost of funds.
New account additions stood at 9.17 lakhs for Q4, with a sourcing mix of 54% from the open market and 46% from banca channels.
👀 What to Watch
Investors should take confidence in the improving asset quality and moderating credit costs, which have been primary concerns for the stock. The company's ability to maintain double-digit NIMs despite a calibrated acquisition strategy makes it a strong hold for long-term credit growth exposure.
SBI Schedules Analyst Meet on May 8, 2026, Following Q4FY26 Results
State Bank of India (SBIN) has announced an interaction with analysts and institutional investors scheduled for May 8, 2026, at 5:15 PM. This meeting will take place immediately following the declaration of the bank's Q4FY26 financial results. The event will be conducted in a hybrid format, featuring an in-person meeting at State Bank Bhavan, Mumbai, alongside a live webcast. This is a critical event for investors to understand the bank's performance trajectory and management's outlook for the next fiscal year.
Key Highlights
Analyst and Institutional Investor meet scheduled for May 8, 2026, at 5:15 PM IST.
The meeting is timed to follow the declaration of Q4FY26 financial results.
Hybrid attendance options provided via in-person meet in Mumbai and a live webcast link.
Management presentation will be made available on stock exchanges and the bank's website post-results.
Discussion will be limited to information already available in the public domain.
👀 What to Watch
Investors should monitor the Q4 results and the subsequent management commentary for insights into credit growth, NIM trends, and asset quality guidance. The webcast link provides a transparent way for retail investors to hear management's strategic priorities firsthand.
Bigbloc Construction Receives Regulatory Approval for Merger of Subsidiary Companies
Bigbloc Construction Limited has received the final order from the Regional Director (NWR) for the merger of its subsidiary, Starbigbloc Building Material Limited, into its wholly-owned subsidiary, Bigbloc Building Elements Private Limited. The merger is effective from the appointed date of April 1, 2025, following approval under Section 233 of the Companies Act, 2013. This internal restructuring is designed to streamline the company's corporate structure and consolidate its building material operations. The official order was pronounced on April 28, 2026, and received by the company on May 2, 2026.
Key Highlights
Merger of Starbigbloc Building Material Ltd into Bigbloc Building Elements Pvt Ltd approved by Regional Director.
The appointed date for the merger is retrospective, set as April 1, 2025.
Restructuring conducted under the fast-track merger provisions of Section 233 of the Companies Act, 2013.
Consolidation aims to achieve operational synergies and reduce administrative overheads across subsidiaries.
👀 What to Watch
Investors should view this as a positive move towards corporate simplification and operational efficiency. No immediate action is required as this is an internal consolidation of existing business units.
Rubicon Research Completes Acquisition of 85% Stake in Arinna Lifesciences
Rubicon Research Limited has successfully completed the secondary acquisition of an 85% stake in Arinna Lifesciences Limited as of April 30, 2026. This transaction follows the initial agreement announced on April 15, 2026, and was executed under the terms of a Share Purchase Agreement. Consequently, Arinna Lifesciences has now become a subsidiary of Rubicon Research. This strategic move is expected to expand Rubicon's footprint and product portfolio in the pharmaceutical and life sciences sector.
Key Highlights
Completed the acquisition of an 85% majority stake in Arinna Lifesciences Limited.
Arinna Lifesciences Limited has officially become a subsidiary of the company as of April 30, 2026.
The acquisition was a secondary purchase following a Share Purchase Agreement dated April 15, 2026.
👀 What to Watch
Investors should view this as a significant expansion move and monitor the upcoming quarterly results for the financial impact and synergy benefits of this acquisition.
BIL Vyapar CoC Discusses Resolution Plan Extension and Valuation in 8th Meeting
BIL Vyapar Limited, currently under the Corporate Insolvency Resolution Process (CIRP), held its 8th Committee of Creditors (CoC) meeting on April 30, 2026. The CoC discussed a request from a prospective resolution applicant for an extension of time to submit a resolution plan. The meeting also addressed the appointment of a co-ordinating valuer and the approval of CIRP costs. Furthermore, the committee is seeking a new accountant to prepare accounts for audit as the previous auditor expressed inability to perform the task.
Key Highlights
Prospective resolution applicant has requested an extension of time for the submission of the Resolution Plan.
CoC noted the valuation methodology and approved the appointment of a Co-ordinating Valuer.
Committee of Creditors officially took note of and approved the CIRP costs incurred.
Search for a new accountant initiated to prepare accounts for audit purposes following the withdrawal of the previous auditor.
👀 What to Watch
Equity shareholders should exercise extreme caution as CIRP proceedings often lead to significant capital erosion or delisting. Monitor the outcome of the resolution plan submission and the valuation reports to understand potential recovery values.
Cantabil Retail Adds 5 New Stores in April 2026, Total Store Count Reaches 658
Cantabil Retail India Limited has announced the opening of 5 new showrooms across various locations in India during the month of April 2026. This expansion brings the company's total retail footprint to 658 stores nationwide. The consistent addition of new outlets indicates a focused strategy on increasing market penetration and brand visibility. Investors should view this as a positive indicator of the company's ongoing organic growth trajectory.
Key Highlights
Opened 5 new showrooms/shops across India in April 2026
Total retail network increased to 658 showrooms/shops
Expansion reported under Regulation 30 of SEBI (LODR) Regulations, 2015
Demonstrates continued physical footprint growth in the retail segment
👀 What to Watch
Investors should monitor the company's quarterly revenue growth to see if the store expansion is translating into higher top-line performance. Watch for management commentary on same-store sales growth (SSSG) in upcoming earnings calls.
ESAB India Appoints Curtis Evan Jewell as Non-Executive Chairman for 5-Year Term
ESAB India Limited has announced the appointment of Mr. Curtis Evan Jewell as its Non-Executive Nominee Director and Non-Executive Chairman, effective May 1, 2026. He replaces Mr. Kevin Johnson following a nomination withdrawal by ESAB Holdings Limited. Mr. Jewell is a Senior Vice President at the global ESAB Corporation and brings extensive experience in corporate governance, M&A, and legal affairs from his tenure at Colfax Corporation and Hogan Lovells. His appointment is for a five-year term and includes chairing the Risk Management Committee.
Key Highlights
Appointment of Curtis Evan Jewell as Non-Executive Chairman for a 5-year term starting May 1, 2026
Withdrawal of nomination for Kevin Johnson (DIN 09147729) effective from the same date
Mr. Jewell currently serves as Senior Vice President and Corporate Secretary at ESAB Corporation
New Chairman will lead the Risk Management Committee and join Audit, NRC, SRC, and CSR committees
Mr. Jewell holds a law degree from UPenn and a business certificate from The Wharton School
👀 What to Watch
This is a routine leadership transition within the parent group's nominee structure; investors should maintain their current positions as the change is unlikely to disrupt operations.
ESAB India Chairman Kevin Johnson Resigns Effective May 1, 2026
ESAB India Limited has announced that Mr. Kevin Johnson will step down as Nominee Director and Chairman effective May 1, 2026. This follows the withdrawal of his nomination by ESAB Holdings Limited due to personal reasons cited by Mr. Johnson. As a result of this cessation, he will also vacate his positions on several key board committees, including his role as Chairman of the Risk Management Committee. The board meeting confirming these changes was held on April 30, 2026, lasting approximately 21 minutes.
Key Highlights
Mr. Kevin Johnson (DIN 09147729) to cease directorship effective May 1, 2026
ESAB Holdings Limited withdrew the nomination via letter dated April 22, 2026
Cessation includes membership in Audit, NRC, Stakeholders' Relationship, and CSR committees
Vacates the position of Chairman of the Risk Management Committee
Board meeting for the announcement concluded at 17:30 hours on April 30, 2026
👀 What to Watch
Investors should watch for the appointment of a new Chairman to ensure smooth leadership transition. This change appears to be a routine administrative withdrawal of a nominee and is unlikely to impact daily operations.
Panacea Biotec Reports Fire at Baddi Oncology Facility; Operations Disrupted for 5-7 Days
Panacea Biotec's subsidiary, Panacea Biotec Pharma Limited, reported a fire incident at its Oncology Quality Control Laboratory in Baddi on April 30, 2026. The fire, caused by a short circuit, was quickly controlled, but operations at the facility are expected to be disrupted for approximately 5 to 7 days. Management has confirmed there were no casualties and that the facility is adequately insured. Importantly, the company does not anticipate a material impact on its overall financial performance due to this temporary halt.
Key Highlights
Fire incident occurred at the Baddi, Himachal Pradesh facility on April 30, 2026, due to a short circuit.
Operations at the Oncology Facility are temporarily disrupted for an estimated period of 5 to 7 days.
Zero human casualties or injuries were reported during the incident.
Management states the disruption is not likely to have a material impact on the company's financials.
The facility has adequate insurance coverage and the insurance company has been notified.
👀 What to Watch
Investors should monitor for a follow-up announcement confirming the resumption of operations within the 7-day window. As the financial impact is expected to be immaterial, no immediate change in investment strategy is required.
IDBI Bank FY26 Net Profit Surges 27% to ₹9,513 Cr; Total Business Crosses ₹6 Trillion
IDBI Bank reported a strong full-year performance for FY26, with net profit growing 27% YoY to ₹9,513 crore, supported by a 14% growth in total business which crossed the ₹6 trillion milestone. While Q4 FY26 net profit saw a slight 5% YoY dip to ₹1,943 crore, the bank maintained exceptional asset quality with a Net NPA of 0.15% and a Provision Coverage Ratio of 99.39%. Capital adequacy remains robust at 26.65%, providing significant headroom for future credit expansion. However, the CASA ratio witnessed a slight compression, falling to 44.59% from 46.55% a year ago.
Key Highlights
Full-year FY26 Net Profit increased by 27% YoY to ₹9,513 crore, while total business grew 14% to ₹6,00,789 crore.
Asset quality significantly improved with Gross NPA falling 66 bps to 2.32% and Net NPA held steady at a very low 0.15%.
Net Interest Income (NII) for Q4 FY26 grew 17% YoY to ₹3,851 crore with NIM improving to 4.15%.
Capital position is exceptionally strong with CRAR at 26.65% and Tier 1 capital at 25.56%.
Net advances grew by 16% YoY to ₹2,53,626 crore, with a retail-to-corporate mix of 70:30.
👀 What to Watch
Investors should focus on the bank's superior asset quality and high capital buffers which provide a strong foundation for credit growth. The consistent PCR above 99% and low Net NPA make it one of the cleanest balance sheets in the Indian banking sector.
IDBI Bank Appoints Abhijit Chakravorty and Ketan Vikamsey as Independent Directors for 2-Year Terms
IDBI Bank has approved the appointment of two seasoned professionals, Shri Abhijit Chakravorty and Shri Ketan Vikamsey, as Additional Independent Directors for two-year terms. Shri Chakravorty brings over 30 years of experience from SBI, including a stint as MD & CEO of SBI Cards. Shri Vikamsey is a senior partner at a major accounting firm and currently serves on the board of SBI. These appointments, effective in May and June 2026 respectively, are expected to strengthen the bank's corporate governance and credit oversight.
Key Highlights
Shri Abhijit Chakravorty appointed for a 2-year term starting May 19, 2026.
Shri Ketan Vikamsey appointed for a 2-year term starting June 26, 2026.
Chakravorty previously served as MD & CEO of SBI Cards & Payment Systems Ltd and has 3 decades of experience at SBI.
Vikamsey is a Senior Partner at KKC & Associates LLP and currently an Independent Director at State Bank of India.
Both appointments are subject to shareholder approval and comply with SEBI (LODR) Regulations.
👀 What to Watch
The addition of high-caliber independent directors with deep banking and audit expertise is a positive signal for corporate governance. Investors should view this as a strengthening of the board's oversight capabilities.
IDBI Bank FY26 Net Profit Rises 26.6% to ₹9,513 Cr; Asset Quality Improves Significantly
IDBI Bank reported a robust performance for the financial year ended March 31, 2026, with a standalone net profit of ₹9,513.30 crore, a 26.6% increase from ₹7,515.17 crore in FY25. The bank's asset quality showed marked improvement, with Gross NPAs falling to 6.02% and Net NPAs reaching a low of 0.38%. Total income for the year grew to ₹35,743.53 crore, driven by steady interest and other income. The bank maintains a very strong capital position with a Capital Adequacy Ratio (CRAR) of 25.05%.
Key Highlights
Annual Net Profit grew by 26.6% YoY to ₹9,513.30 crore from ₹7,515.17 crore
Gross NPA ratio improved to 6.02% as of March 31, 2026, compared to 6.99% YoY
Net NPA ratio decreased to 0.38% from 0.48% in the previous financial year
Capital Adequacy Ratio (CRAR) remains robust at 25.05% with Tier 1 at 23.51%
Annualized Return on Assets (ROA) for FY26 stood at a healthy 2.96%
👀 What to Watch
The consistent improvement in asset quality and strong profitability metrics make IDBI Bank a stable hold for long-term investors. Monitor the ongoing privatization process as it remains the primary catalyst for significant stock re-rating.
Panacea Biotec Wins Tax Appeal; ITAT Cancels ₹9.16 Crore Demand
Panacea Biotec has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding Assessment Year 2020-21. The ITAT set aside a previous order that had raised a tax demand of ₹9.16 Crore. This demand was originally based on a ₹3.44 Crore disallowance of expenses under Section 14A of the Income Tax Act. The ruling effectively cancels the entire demand, providing a positive financial impact for the company by removing this liability.
Key Highlights
ITAT set aside the CIT(A) order dated August 14, 2025, for Assessment Year 2020-21
Cancellation of a tax demand amounting to ₹9.16 Crore
Deletion of expense disallowance of ₹3.44 Crore previously added under Section 14A
The ruling follows a Rectified Assessment Order originally passed on October 10, 2023
👀 What to Watch
This is a positive development as it removes a contingent liability and improves the company's financial position. Investors should continue to monitor the company's core business performance alongside such legal resolutions.
Biocon Receives 5 Procedural Observations from US FDA for Bengaluru Biosimilars Site
The U.S. FDA concluded a Pre-License Inspection at Biocon's Bengaluru biosimilars facility on April 29, 2026. The inspection covered 10 distinct areas including 3 manufacturing units, 5 labs, and 2 warehouses, resulting in a Form 483 with five observations. Biocon has stated these observations are procedural and do not involve data integrity or quality oversight issues. The company is now preparing a Corrective and Preventive Action (CAPA) plan to address the findings within the required timeline.
Key Highlights
Inspection conducted between April 20 and April 29, 2026, at Biocon Park, Bengaluru.
US FDA issued Form 483 with 5 observations across 3 manufacturing units and 5 labs.
Observations are procedural in nature with no data integrity or quality oversight concerns.
Zero repeat observations were noted during the conclusion of the audit.
Company to submit a comprehensive CAPA plan to address all observations expeditiously.
👀 What to Watch
Investors should monitor the final classification of the inspection by the US FDA; while procedural observations are common, successful resolution is required for future product approvals from this site.
Bikaji Foods Promoters Confirm Zero Pledged Shares for FY26; Hold 73.88% Stake
Bikaji Foods' promoters have submitted their annual declaration confirming that no shares were pledged or encumbered during the financial year ended March 31, 2026. The promoter group collectively holds 18,52,39,398 shares, representing a significant 73.878% stake in the company. Key individual holders include Shiv Ratan Agarwal (33.70%) and Shiv Ratan Agarwal HUF (24.41%). This disclosure provides transparency regarding the stability of the promoter holding and the absence of debt-related risks associated with share pledging.
Key Highlights
Promoter group holds a total of 18,52,39,398 equity shares as of March 31, 2026.
Total promoter stake stands at 73.878% of the company's equity.
Zero shares were encumbered or pledged, directly or indirectly, during FY 2025-26.
Major shareholders include Shiv Ratan Agarwal (33.698%) and Deepak Agarwal (14.300%).
👀 What to Watch
The absence of pledged shares is a positive indicator of promoter financial health. Long-term investors can remain confident in the stability of the current shareholding structure.
Gufic Biosciences Invests USD 50,000 in Australian Biotech Firm Selvax
Gufic Biosciences has increased its stake in Selvax Pty Ltd, an Australian biotechnology company, by investing USD 50,000. The company subscribed to 378,350 ordinary shares at AUD 20 cents per share, bringing its total holding to 1,685,350 shares. This strategic investment is aimed at diversifying into the oncology immunotherapy sector, focusing on treatments for large solid tumors in humans and animals. Selvax has shown steady revenue growth, with its total income rising to AUD 356,972 for the year ended June 30, 2025.
Key Highlights
Investment of USD 50,000 for 378,350 ordinary shares at AUD 20 cents per share.
Total post-acquisition shareholding in Selvax increased to 1,685,350 shares.
Selvax's annual income grew from AUD 220,435 in 2023 to AUD 356,972 in 2025.
Strategic focus on proprietary immunotherapy for solid tumors including lung, pancreatic, and breast cancer.
👀 What to Watch
Investors should monitor this as a long-term strategic play in the high-growth oncology segment; while the current investment is small, successful commercialization of Selvax's technology could provide significant upside.
